カテゴリー： 世界, 医療/バイオ, Market Research Future

世界の尋常性白斑治療市場（〜2030年）

【英語タイトル】Vitiligo Treatment Market Forecast till 2030

Market Research Futureが出版した調査資料（MRF23AP054）・商品コード：MRF23AP054
・発行会社（調査会社）：Market Research Future
・発行日：2023年3月7日
・ページ数：122
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール
・調査対象地域：グローバル
・産業分野：医療
◆販売価格オプション（消費税別）
Single User（印刷不可、Online Access）USD4,950 ⇒換算￥752,400見積依頼/購入/質問フォーム
Enterprisewide Price（印刷可）USD7,250 ⇒換算￥1,102,000見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

Market Research Future社の市場調査レポートでは、世界の尋常性白斑治療市場規模が予測期間中に年平均6.20％成長すると推測されています。当レポートでは、尋常性白斑治療の世界市場を対象に調査・分析を行い、エグゼクティブサマリー、イントロダクション、調査手法、市場動向、市場要因分析、種類別（分節型尋常性白斑、非分節型尋常性白斑）分析、治療種類別（治療、手術、投薬）分析、エンドユーザー別（病院、外来診療所、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、その他地域）分析、競争状況、企業情報など、以下の構成でまとめています。また、市場調査の対象企業には、Incyte (US)、Koninklijke Philips N.V. (Netherlands)、Bausch Health Companies Inc. (Canada)、Reddy's Laboratories Ltd. (India)、STRATA Skin Sciences (US)、Clinuvel Pharmaceuticals Ltd (Australia)、Roivant Sciences Ltd. (Switzerland)などが含まれています。
・エグゼクティブサマリー
・イントロダクション
・調査手法
・市場動向
・市場要因分析
・世界の尋常性白斑治療市場規模：種類別
- 分節型尋常性白斑の市場規模
- 非分節型尋常性白斑の市場規模
・世界の尋常性白斑治療市場規模：治療種類別
- 治療における市場規模
- 手術における市場規模
- 投薬における市場規模
・世界の尋常性白斑治療市場規模：エンドユーザー別
- 病院における市場規模
- 外来診療所における市場規模
- その他エンドユーザーにおける市場規模
・世界の尋常性白斑治療市場規模：種類別
・世界の尋常性白斑治療市場規模：地域別
- 北米の尋常性白斑治療市場規模
- ヨーロッパの尋常性白斑治療市場規模
- アジア太平洋の尋常性白斑治療市場規模
- その他地域の尋常性白斑治療市場規模
・競争状況
・企業情報

尋常性白斑治療市場調査レポート 2030年までの予測

市場概要：
尋常性白斑治療市場は、調査期間中にCAGR 6.20%を記録すると予測されます。白斑は、メラノサイトとして知られる皮膚の色伝達細胞の機能不全または死滅によってもたらされる皮膚の色素脱失によって描かれる、持続的な皮膚科学的問題です。そのため、皮膚にはっきりとした白い斑点が現れます。このような状況が続くと、皮膚の広い範囲が色を失います。治療によって皮膚の外観がさらに改善されるかもしれませんが、病気は治りません。世界的な尋常性白斑治療市場を牽引する主な要因は、センスの良い魅力と心遣いの意義の発展、白斑症例の一般性の上昇です。混乱によってもたらされる様々な困難を治療するための治療法を提案する技術革新の進歩、医療基盤における政府機関による思索の浸透が市場発展を加速させています。
最近では、様々なスタイルの治療法、一人当たりの給与の拡大、およびコンピュータ化されたステージの受信についての買い物客の間で発展しているマインドフルネスから推測される顧客の間で卓越した認識の巨大な上昇があります。Global Society of Stylish Plastic Medical procedure（ISAPS）によると、2015年から2019年の間のどこかの範囲において、全体的な完全な非手術に27.3％の発展がありました。さらに、アメリカ形成専門家文化（ASPS）が示すように、過少に侵入する味わい深いシステムの量は、2000年から2017年の間に約200％の拡大を見ました。その上、2018年には、2017年とは対照的に2％上昇した約1,590万件の無視できるほど侵入的な修復方法が行われました。その後、高齢者人口が増加していることが、さらに無視できるほど目立たない修復方法への関心を高めています。

セグメント概要：
タイプ別では、尋常性白斑治療市場は分節性白斑と非分節性白斑に分けられます。治療タイプ別では、市場は手術、治療、投薬に分類されます。
エンドユーザー産業別では、市場は外来診療所、病院、その他に分けられます。

地域分析：
北米は2021年に世界の尋常性白斑治療市場を支配しました。これは、返済運動の存在と、同様に地域市場の発展に拍車をかけている趣味の良い魅力の発展の意義によるものです。
Journal of the European Foundation of Dermatology and Venereology (JEADV)に掲載された記事によると、オンライン人口ベースの調査では、ヨーロッパにおける白斑の罹患率は1.3%でした。また、この地域では、尋常性白斑治療戦略の機械的な進歩が進んでいます。
アジア太平洋地域の尋常性白斑治療市場は、革新的な治療法の拡大や尋常性白斑治療の選択肢に対する関心の高まりによって牽引されています。例えば、Indian Dermatology Online Diary (IDOJ)が示すように、200人の白斑患者を対象とした横断的レビューが行われ、16.5%の人が分節性白斑であり、83.5%の人が非分節性白斑であったことが示されています。また、この地域における買収、共同努力、行政の承認、利益など、さまざまな公的機関や秘密団体による推進活動の数が増加していることも、市場発展の一助となっています。

主要企業：
この市場調査における主要企業には、Incyte (US), Koninklijke Philips N.V. (Netherlands), Bausch Health Companies Inc. (Canada), Reddy’s Laboratories Ltd. (India), STRATA Skin Sciences (US), Clinuvel Pharmaceuticals Ltd (Australia), Roivant Sciences Ltd. (Switzerland), ISSAR Pharmaceuticals Pvt. Ltd. (India), Kernel Medical Equipment Co., LTD. (China), and LightSource (US)などが含まれます。

新型コロナウイルスの影響：
私たちは、新型コロナウイルスパンデミックがあらゆる分野のさまざまな業界や業種に与える影響を継続的に追跡しています。当社の調査レポートでは、新型コロナウイルスの産業への影響による減少や上昇を把握することができます。また、貴社が関心をお持ちの市場の需要と供給のギャップを特定するのにも役立ちます。さらに、このレポートは、分析、改正された政府規制、その他多くの有用な洞察を支援します。

グローバル市場調査レポート販売サイトのwww.marketreport.jpです。

❖ レポートの目次 ❖

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

1.1 OVERVIEW

1.1.1 MARKET SYNOPSIS

2 MARKET INTRODUCTION

2.1 DEFINITION

2.2 SCOPE OF THE STUDY

2.3 RESEARCH OBJECTIVE

2.4 LIST OF ASSUMPTIONS

3 RESEARCH METHODOLOGY

3.1 OVERVIEW

3.2 DATA MINING

3.3 SECONDARY RESEARCH

3.4 PRIMARY RESEARCH

3.4.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS

3.4.2 BREAKDOWN OF PRIMARY RESPONDENTS

3.5 FORECASTING TECHNIQUES

3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION

3.6.1 BOTTOM-UP APPROACH

3.6.2 TOP-DOWN APPROACH

3.7 DATA TRIANGULATION

3.8 VALIDATION

4 MARKET DYNAMICS

4.1 OVERVIEW

4.2 DRIVERS

4.2.1 GROWING IMPORTANCE OF THE AESTHETIC APPEAL AND AWARENESS

4.2.2 INCREASING PREVALENCE OF VITLIGO

4.3 RESTRAINTS

4.3.1 LACK OF TRAINED PROFESSIONALS

4.4 OPPORTUNITIES

4.4.1 RISING NUMBER OF CLINICAL TRIALS

5 MARKET FACTOR ANALYSIS

5.1 VALUE CHAIN ANALYSIS

5.1.1 R&D

5.1.2 MANUFACTURING

5.1.3 DISTRIBUTION & SALES

5.1.4 POST-SALES MONITORING

5.2 PORTER’S FIVE FORCES MODEL

5.2.1 THREAT OF NEW ENTRANTS

5.2.2 BARGAINING POWER OF SUPPLIERS

5.2.3 THREAT OF SUBSTITUTES

5.2.4 BARGAINING POWER OF BUYERS

5.2.5 INTENSITY OF RIVALRY

5.3 IMPACT OF COVID-19 ON THE VITILIGO TREATMENT MARKET

5.3.1 IMPACT ON SUPPLY CHAIN

5.3.2 IMPACT ON REGION

5.3.3 IMPACT ON DEMAND AND SUPPLY

6 GLOBAL VITILIGO TREATMENT MARKET, BY TYPE

6.1 OVERVIEW

6.2 SEGMENTAL VITILIGO

6.3 NON-SEGMENTAL VITILIGO

7 GLOBAL VITILIGO TREATMENT MARKET, BY TREATMENT TYPE

7.1 OVERVIEW

7.2 THERAPY

7.2.1 DEPIGMENTATION

7.2.2 LIGHT

7.3 SURGERY

7.3.1 SKIN GRAFTING

7.3.2 BLISTER GRAFTING

7.3.3 MICRO-PIGMENTATION

7.4 MEDICATION

7.4.1 TOPICAL CORTICOSTEROIDS

7.4.2 IMMUNOSUPPRESSIVE

8 GLOBAL VITILIGO TREATMENT MARKET, BY END USER

8.1 OVERVIEW

8.2 HOSPITALS

8.3 AMBULATORY CLINICS

8.4 OTHERS

9 GLOBAL VITILIGO TREATMENT MARKET, BY REGION

9.1 OVERVIEW

9.2 NORTH AMERICA

9.2.1 US

9.2.2 CANADA

9.3 EUROPE

9.3.1 GERMANY

9.3.2 FRANCE

9.3.3 UK

9.3.4 ITALY

9.3.5 SPAIN

9.3.6 REST OF EUROPE

9.4 ASIA-PACIFIC

9.4.1 CHINA

9.4.2 JAPAN

9.4.3 INDIA

9.4.4 SOUTH KOREA

9.4.5 AUSTRALIA

9.4.6 REST OF ASIA-PACIFIC

9.5 REST OF THE WORLD

9.5.1 MIDDLE EAST

9.5.2 AFRICA

9.5.3 LATIN AMERICA

10 COMPETITIVE LANDSCAPE

10.1 OVERVIEW

10.2 COMPETITIVE BENCHMARKING

10.3 MAJOR GROWTH STRATEGY IN VITILIGO TREATMENT MARKET

10.4 THE LEADING PLAYER IN TERMS OF NUMBER OF DEVELOPMENTS IN VITILIGO TREATMENT MARKET

10.5 KEY DEVELOPMENT ANALYSIS

10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES

10.6.1 PRODUCT APPROVALS/PRODUCT LAUNCHES/DRUG PIPELINE

10.6.2 MERGERS & ACQUISITIONS

10.7 MAJOR PLAYERS SALES ANALYSIS

10.7.1 SALES & OPERATING INCOME, 2021

10.7.2 MAJOR PLAYERS R&D ANALYSIS, 2021

11 COMPANY PROFILE

11.1 INCYTE

11.1.1 COMPANY OVERVIEW

11.1.2 FINANCIAL OVERVIEW

11.1.3 PRODUCTS OFFERED

11.1.4 KEY DEVELOPMENTS

11.1.5 SWOT ANALYSIS

11.1.6 KEY STRATEGIES

11.2 BAUSCH HEALTH COMPANIES INC.

11.2.1 COMPANY OVERVIEW

11.2.2 FINANCIAL OVERVIEW

11.2.3 PRODUCTS OFFERED

11.2.4 KEY DEVELOPMENTS

11.2.5 SWOT ANALYSIS

11.2.6 KEY STRATEGIES

11.3 KONINKLIJKE PHILIPS N.V.

11.3.1 COMPANY OVERVIEW

11.3.2 FINANCIAL OVERVIEW

11.3.3 PRODUCTS OFFERED

11.3.4 KEY DEVELOPMENTS

11.3.5 SWOT ANALYSIS

11.3.6 KEY STRATEGIES

11.4 DR. REDDY’S LABORATORIES LTD.

11.4.1 COMPANY OVERVIEW

11.4.2 FINANCIAL OVERVIEW

11.4.3 PRODUCTS OFFERED

11.4.4 KEY DEVELOPMENTS

11.4.5 SWOT ANALYSIS

11.4.6 KEY STRATEGIES

11.5 STRATA SKIN SCIENCES

11.5.1 COMPANY OVERVIEW

11.5.2 FINANCIAL OVERVIEW

11.5.3 PRODUCTS OFFERED

11.5.4 KEY DEVELOPMENTS

11.5.5 KEY STRATEGIES

11.6 CLINUVEL PHARMACEUTICALS LTD

11.6.1 COMPANY OVERVIEW

11.6.2 FINANCIAL OVERVIEW

11.6.3 PRODUCTS OFFERED

11.6.4 KEY DEVELOPMENTS

11.6.5 SWOT ANALYSIS

11.6.6 KEY STRATEGIES

11.7 ISSAR PHARMACEUTICALS PVT. LTD.

11.7.1 COMPANY OVERVIEW

11.7.2 FINANCIAL ANALYSIS

11.7.3 PRODUCTS OFFERED

11.7.4 KEY DEVELOPMENTS

11.7.5 KEY STRATEGIES

11.8 KERNEL MEDICAL EQUIPMENT CO., LTD.

11.8.1 COMPANY OVERVIEWS

11.8.2 FINANCIAL OVERVIEW

11.8.3 PRODUCTS OFFERED

11.8.4 KEY DEVELOPMENTS

11.8.5 KEY STRATEGIES

11.9 LIGHTSOURCES

11.9.1 COMPANY OVERVIEW

11.9.2 FINANCIAL ANALYSIS

11.9.3 PRODUCTS OFFERED

11.9.4 KEY DEVELOPMENTS

11.9.5 KEY STRATEGIES

11.10 ROIVANT SCIENCES LTD.

11.10.1 COMPANY OVERVIEW

11.10.2 FINANCIAL ANALYSIS

11.10.3 PRODUCTS OFFERED

11.10.4 KEY DEVELOPMENTS

11.10.5 PRODUCTS OFFERED

11.10.6 KEY STRATEGIES

12 APPENDIX

12.1 REFERENCES

12.2 RELATED REPORTS

LIST OF TABLES

TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS

TABLE 2 GLOBAL VITILIGO TREATMENT MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 3 GLOBAL VITILIGO TREATMENT MARKET, FOR SEGMENTAL VITILIGO, BY REGION, 2018–2030 (USD MILLION)

TABLE 4 GLOBAL VITILIGO TREATMENT MARKET, FOR NON-SEGMENTAL VITILIGO, BY REGION, 2018–2030 (USD MILLION)

TABLE 5 GLOBAL VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2018–2030 (USD MILLION)

TABLE 6 GLOBAL VITILIGO TREATMENT MARKET, FOR THERAPY, BY REGION, 2018–2030 (USD MILLION)

TABLE 7 GLOBAL VITILIGO TREATMENT MARKET, FOR DEPIGMENTATION, BY REGION, 2018–2030 (USD MILLION)

TABLE 8 GLOBAL VITILIGO TREATMENT MARKET, FOR LIGHT, BY REGION, 2018–2030 (USD MILLION)

TABLE 9 GLOBAL VITILIGO TREATMENT MARKET, FOR SURGERY, BY REGION, 2018–2030 (USD MILLION)

TABLE 10 GLOBAL VITILIGO TREATMENT MARKET, FOR SKIN GRAFTING, BY REGION, 2018–2030 (USD MILLION)

TABLE 11 GLOBAL VITILIGO TREATMENT MARKET, FOR BLISTER GRAFTING, BY REGION, 2018–2030 (USD MILLION)

TABLE 12 GLOBAL VITILIGO TREATMENT MARKET, FOR MICRO-PIGMENTATION, BY REGION, 2018–2030 (USD MILLION)

TABLE 13 GLOBAL VITILIGO TREATMENT MARKET, FOR MEDICATION, BY REGION, 2018–2030 (USD MILLION)

TABLE 14 GLOBAL VITILIGO TREATMENT MARKET, FOR TOPICAL CORTICOSTEROIDS, BY REGION, 2018–2030 (USD MILLION)

TABLE 15 GLOBAL VITILIGO TREATMENT MARKET, FOR IMMUNOSUPPRESSIVE, BY REGION, 2018–2030 (USD MILLION)

TABLE 16 GLOBAL VITILIGO TREATMENT MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 17 GLOBAL VITILIGO TREATMENT MARKET, FOR HOSPITALS, BY REGION, 2018–2030 (USD MILLION)

TABLE 18 GLOBAL VITILIGO TREATMENT MARKET, FOR AMBULATORY CLINICS, BY REGION, 2018–2030 (USD MILLION)

TABLE 19 GLOBAL VITILIGO TREATMENT MARKET, FOR OTHERS, BY REGION, 2018–2030 (USD MILLION)

TABLE 20 GLOBAL: VITILIGO TREATMENT MARKET, BY REGION, 2018–2030 (USD MILLION)

TABLE 21 NORTH AMERICA: VITILIGO TREATMENT MARKET, BY COUNTRY, 2018–2030 (USD MILLION)

TABLE 22 NORTH AMERICA: VITILIGO TREATMENT MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 23 NORTH AMERICA: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2018–2030 (USD MILLION)

TABLE 24 NORTH AMERICA: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 25 NORTH AMERICA: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 26 NORTH AMERICA: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2018–2030 (USD MILLION)

TABLE 27 NORTH AMERICA: VITILIGO TREATMENT MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 28 US: VITILIGO TREATMENT MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 29 US: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2018–2030 (USD MILLION)

TABLE 30 US: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 31 US: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 32 US: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2018–2030 (USD MILLION)

TABLE 33 US: VITILIGO TREATMENT MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 34 CANADA: VITILIGO TREATMENT MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 35 CANADA: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2018–2030 (USD MILLION)

TABLE 36 CANADA: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 37 CANADA: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 38 CANADA: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2018–2030 (USD MILLION)

TABLE 39 CANADA: VITILIGO TREATMENT MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 40 EUROPE: VITILIGO TREATMENT MARKET, BY COUNTRY, 2018–2030 (USD MILLION)

TABLE 41 EUROPE: VITILIGO TREATMENT MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 42 EUROPE: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2018–2030 (USD MILLION)

TABLE 43 EUROPE: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 44 EUROPE: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 45 EUROPE: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2018–2030 (USD MILLION)

TABLE 46 EUROPE: VITILIGO TREATMENT MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 47 GERMANY: VITILIGO TREATMENT MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 48 GERMANY: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2018–2030 (USD MILLION)

TABLE 49 GERMANY: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 50 GERMANY: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 51 GERMANY: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2018–2030 (USD MILLION)

TABLE 52 GERMANY: VITILIGO TREATMENT MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 53 FRANCE: VITILIGO TREATMENT MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 54 FRANCE: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2018–2030 (USD MILLION)

TABLE 55 FRANCE: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 56 FRANCE: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 57 FRANCE: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2018–2030 (USD MILLION)

TABLE 58 FRANCE: VITILIGO TREATMENT MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 59 UK: VITILIGO TREATMENT MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 60 UK: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2018–2030 (USD MILLION)

TABLE 61 UK: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 62 UK: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 63 UK: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2018–2030 (USD MILLION)

TABLE 64 UK: VITILIGO TREATMENT MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 65 ITALY: VITILIGO TREATMENT MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 66 ITALY: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2018–2030 (USD MILLION)

TABLE 67 ITALY: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 68 ITALY: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 69 ITALY: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2018–2030 (USD MILLION)

TABLE 70 ITALY: VITILIGO TREATMENT MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 71 SPAIN: VITILIGO TREATMENT MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 72 SPAIN: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2018–2030 (USD MILLION)

TABLE 73 SPAIN: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 74 SPAIN: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 75 SPAIN: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2018–2030 (USD MILLION)

TABLE 76 SPAIN: VITILIGO TREATMENT MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 77 REST OF EUROPE: VITILIGO TREATMENT MARKET, BY TYPE, 2018–2030 (USD MILLION)

TABLE 78 REST OF EUROPE: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2018–2030 (USD MILLION)

TABLE 79 REST OF EUROPE: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 80 REST OF EUROPE: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 81 REST OF EUROPE: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2018–2030 (USD MILLION)

TABLE 82 REST OF EUROPE: VITILIGO TREATMENT MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 83 ASIA-PACIFIC: VITILIGO TREATMENT MARKET, BY COUNTRY, 2018-2030 (USD MILLION)

TABLE 84 ASIA-PACIFIC: VITILIGO TREATMENT MARKET, BY TYPE, 2018-2030 (USD MILLION)

TABLE 85 ASIA-PACIFIC: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2018-2030 (USD MILLION)

TABLE 86 ASIA-PACIFIC: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2018-2030 (USD MILLION)

TABLE 87 ASIA-PACIFIC: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2018-2030 (USD MILLION)

TABLE 88 ASIA-PACIFIC: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2018-2030 (USD MILLION)

TABLE 89 ASIA-PACIFIC: VITILIGO TREATMENT MARKET, BY END USER, 2018-2030 (USD MILLION)

TABLE 90 CHINA: VITILIGO TREATMENT MARKET, BY TYPE, 2018-2030 (USD MILLION)

TABLE 91 CHINA: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2018-2030 (USD MILLION)

TABLE 92 CHINA: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2018-2030 (USD MILLION)

TABLE 93 CHINA: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2018-2030 (USD MILLION)

TABLE 94 CHINA: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2018-2030 (USD MILLION)

TABLE 95 CHINA: VITILIGO TREATMENT MARKET, BY END USER, 2018-2030 (USD MILLION)

TABLE 96 JAPAN: VITILIGO TREATMENT MARKET, BY TYPE, 2018-2030 (USD MILLION)

TABLE 97 JAPAN: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2018-2030 (USD MILLION)

TABLE 98 JAPAN: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2018-2030 (USD MILLION)

TABLE 99 JAPAN: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2018-2030 (USD MILLION)

TABLE 100 JAPAN: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2018-2030 (USD MILLION)

TABLE 101 JAPAN: VITILIGO TREATMENT MARKET, BY END USER, 2018-2030 (USD MILLION)

TABLE 102 INDIA: VITILIGO TREATMENT MARKET, BY TYPE, 2018-2030 (USD MILLION)

TABLE 103 INDIA: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2018-2030 (USD MILLION)

TABLE 104 INDIA: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2018-2030 (USD MILLION)

TABLE 105 INDIA: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2018-2030 (USD MILLION)

TABLE 106 INDIA: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2018-2030 (USD MILLION)

TABLE 107 INDIA: VITILIGO TREATMENT MARKET, BY END USER, 2018-2030 (USD MILLION)

TABLE 108 SOUTH KOREA: VITILIGO TREATMENT MARKET, BY TYPE, 2018-2030 (USD MILLION)

TABLE 109 SOUTH KOREA: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2018-2030 (USD MILLION)

TABLE 110 SOUTH KOREA: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2018-2030 (USD MILLION)

TABLE 111 SOUTH KOREA: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2018-2030 (USD MILLION)

TABLE 112 SOUTH KOREA: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2018-2030 (USD MILLION)

TABLE 113 SOUTH KOREA: VITILIGO TREATMENT MARKET, BY END USER, 2018-2030 (USD MILLION)

TABLE 114 AUSTRALIA: VITILIGO TREATMENT MARKET, BY TYPE, 2018-2030 (USD MILLION)

TABLE 115 AUSTRALIA: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2018-2030 (USD MILLION)

TABLE 116 AUSTRALIA: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2018-2030 (USD MILLION)

TABLE 117 AUSTRALIA: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2018-2030 (USD MILLION)

TABLE 118 AUSTRALIA: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2018-2030 (USD MILLION)

TABLE 119 AUSTRALIA: VITILIGO TREATMENT MARKET, BY END USER, 2018-2030 (USD MILLION)

TABLE 120 REST OF ASIA-PACIFIC: VITILIGO TREATMENT MARKET, BY TYPE, 2018-2030 (USD MILLION)

TABLE 121 REST OF ASIA-PACIFIC: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2018-2030 (USD MILLION)

TABLE 122 REST OF ASIA-PACIFIC: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2018-2030 (USD MILLION)

TABLE 123 REST OF ASIA-PACIFIC: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2018-2030 (USD MILLION)

TABLE 124 REST OF ASIA-PACIFIC: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2018-2030 (USD MILLION)

TABLE 125 REST OF ASIA-PACIFIC: VITILIGO TREATMENT MARKET, BY END USER, 2018-2030 (USD MILLION)

TABLE 126 REST OF THE WORLD: VITILIGO TREATMENT MARKET, BY COUNTRY, 2018-2030 (USD MILLION)

TABLE 127 REST OF THE WORLD: VITILIGO TREATMENT MARKET, BY TYPE, 2018-2030 (USD MILLION)

TABLE 128 REST OF THE WORLD: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2018-2030 (USD MILLION)

TABLE 129 REST OF THE WORLD: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2018-2030 (USD MILLION)

TABLE 130 REST OF THE WORLD: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2018-2030 (USD MILLION)

TABLE 131 REST OF THE WORLD: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2018-2030 (USD MILLION)

TABLE 132 REST OF THE WORLD: VITILIGO TREATMENT MARKET, BY END USER, 2018-2030 (USD MILLION)

TABLE 133 MIDDLE EAST: VITILIGO TREATMENT MARKET, BY TYPE, 2018-2030 (USD MILLION)

TABLE 134 MIDDLE EAST: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2018-2030 (USD MILLION)

TABLE 135 MIDDLE EAST: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2018-2030 (USD MILLION)

TABLE 136 MIDDLE EAST: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2018-2030 (USD MILLION)

TABLE 137 MIDDLE EAST: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2018-2030 (USD MILLION)

TABLE 138 MIDDLE EAST: VITILIGO TREATMENT MARKET, BY END USER, 2018-2030 (USD MILLION)

TABLE 139 AFRICA: VITILIGO TREATMENT MARKET, BY TYPE, 2018-2030 (USD MILLION)

TABLE 140 AFRICA: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2018-2030 (USD MILLION)

TABLE 141 AFRICA: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2018-2030 (USD MILLION)

TABLE 142 AFRICA: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2018-2030 (USD MILLION)

TABLE 143 AFRICA: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2018-2030 (USD MILLION)

TABLE 144 AFRICA: VITILIGO TREATMENT MARKET, BY END USER, 2018-2030 (USD MILLION)

TABLE 145 LATIN AMERICA: VITILIGO TREATMENT MARKET, BY TYPE, 2018-2030 (USD MILLION)

TABLE 146 LATIN AMERICA: VITILIGO TREATMENT MARKET, BY TREATMENT TYPE, 2018-2030 (USD MILLION)

TABLE 147 LATIN AMERICA: VITILIGO TREATMENT MARKET, FOR THERAPY, BY TYPE, 2018-2030 (USD MILLION)

TABLE 148 LATIN AMERICA: VITILIGO TREATMENT MARKET, FOR SURGERY, BY TYPE, 2018-2030 (USD MILLION)

TABLE 149 LATIN AMERICA: VITILIGO TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2018-2030 (USD MILLION)

TABLE 150 LATIN AMERICA: VITILIGO TREATMENT MARKET, BY END USER, 2018-2030 (USD MILLION)

TABLE 151 MAJOR MANUFACTURERS IN VITILIGO TREATMENT MARKET

TABLE 152 MOST ACTIVE PLAYER IN VITILIGO TREATMENT MARKET

TABLE 153 PRODUCT APPROVALS/PRODUCT LAUNCHES/DRUG PIPELINE

TABLE 154 MERGERS & ACQUISITIONS

TABLE 155 INCYTE: PRODUCTS OFFERED

TABLE 156 INCYTE: KEY DEVELOPMENTS

TABLE 157 BAUSCH HEALTH COMPANIES INC.: PRODUCTS OFFERED

TABLE 158 KONINKLIJKE PHILIPS N.V.: PRODUCTS OFFERED

TABLE 159 DR. REDDY'S LABORATORIES LTD.: PRODUCTS OFFERED

TABLE 160 STRATA SKIN SCIENCES: PRODUCTS OFFERED

TABLE 161 STRATA SKIN SCIENCES: KEY DEVELOPMENTS

TABLE 162 CLINUVEL PHARMACEUTICALS LTD: PRODUCTS OFFERED

TABLE 163 ISSAR PHARMACEUTICALS PVT. LTD.: PRODUCTS OFFERED

TABLE 164 KERNEL MEDICAL EQUIPMENT CO., LTD.: PRODUCTS OFFERED

TABLE 165 LIGHTSOURCES: PRODUCTS OFFERED

TABLE 166 ROIVANT SCIENCES LTD.: PRODUCTS OFFERED

★調査レポート[世界の尋常性白斑治療市場（〜2030年）] (コード：MRF23AP054)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の尋常性白斑治療市場（〜2030年）]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界のポンペ病治療市場（〜2030年）
  • 血栓治療の世界市場予測（～2030年）
  • 世界のダーカム病市場（〜2030年）
  • 世界の食道扁平上皮がん市場（〜2030年）
  • 世界の骨生検市場（〜2030年）
  • 世界の痛風市場（〜2030年）
  • タイの美容医療市場（〜2030年）
  • 世界のHERGスクリーニング市場（〜2030年）
  • 世界のコーティング下処理市場（〜2030年）

    • ◆H&Iグローバルリサーチのお客様（例）◆